GCG and hydrops fetalis: SGLT-2 inhibitors and GLP-1 RAs both significantly lowered the risk of MACE, hospitalisation for HF, and renal composite outcome when compared to placebo and DPP-4 inhibitors, respectively (Table 2 and Fig. 2).